Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: The dialectical nature of subtle human immune dysregulation

Cancer Research

Volumn 69, Issue 15, 2009, Pages 6011-6014

  Sun, Tong ^a,c   Hu, Zhibin ^b   Shen, Hongbing ^b   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

AUTOIMMUNE DISEASE; CANCER SUSCEPTIBILITY; CELLULAR IMMUNITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNE DYSREGULATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, CD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 68049123433     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0176     Document Type: Review

References (32)

1. Clark WH, Jr., Elder DE, Guerry D, 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904
2. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213 (Pubitemid 36077915)
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998 (Pubitemid 35363648)
4. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001;1:220-228
5. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006;24:65-97.
6. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-618
7. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes Immun 2000;1:170-184
8. Wang XB, Zhao X, Giscombe R, Lefvert AKA. CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002;3:233-234 (Pubitemid 38961137)
9. Chistiakov DA, Savost'anov KV, Turakulov RI, Efremov IA, Demurov LM. Genetic analysis and functional evaluation of the C/T(-318) and A/ G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves' disease. Clin Immunol 2006;118:233-242
10. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001;2:145-152 (Pubitemid 33674879)
11. Anjos SM, Tessier MC, Polychronakos C. Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block. J Clin Endocrinol Metab 2004;89:6257-6265 (Pubitemid 39628442)
12. Nistico L, Buzzetti R, Pritchard LE, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996;5:1075-1080 (Pubitemid 26232296)
13. Donnadieu E, Cookson WO, Jouvin MH, Kinet JP. Allergy-associated polymorphisms of the Fc epsilon RI h subunit do not impact its two amplification functions. J Immunol 2000;165:3917-3922 (Pubitemid 32057300)
14. Mäurer M, Loserth S, Kolb-Mäurer A, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002;54:1-8. (Pubitemid 34492947)
15. Xu Y, Graves PN, Tomer Y, Davies TF. CTLA-4 and autoimmune thyroid disease: lack of influence of the A49G signal peptide polymorphism on functional recombinant human CTLA-4. Cell Immunol 2002;215:133-140
16. Sun T, Zhou Y, Yang M, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008;68:7025-7034
17. Saverino D, Brizzolara R, Simone R, et al. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin Immunol 2007;123:190-198 (Pubitemid 46590071)
18. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-511 (Pubitemid 36648570)
19. Lee YH, Harley JB, Nath SK. CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a metaanalysis. Hum Genet 2005;116:361-367 (Pubitemid 40521112)
20. Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE Review and meta-analysis. Am J Epidemiol 2005;162:3-16.
21. Kavvoura FK, Akamizu T, Awata T, et al. Cytotoxic Tlymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. J Clin Endocrinol Metab 2007;92:3162-3170 (Pubitemid 47240945)
22. Wang L, Li D, Fu Z, Li H, Jiang W, Li D. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 2007;7:173.
23. Erfani N, Razmkhah M, Talei AR, et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 2006;165:114-120 (Pubitemid 43343504)
24. Ghaderi A, Yeganeh F, Kalantari T, et al. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 2004;86:1-7. (Pubitemid 38918893)
25. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 2007;22:2283-2287 (Pubitemid 350145629)
26. Dilmec F, Ozgonul A, Uzunkoy A, Akkafa F. Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet 2008;35:317-321
27. Cozar JM, Romero JM, Aptsiauri N, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007;68:698-704. (Pubitemid 47126657)
28. Wong YK, Chang KW, Cheng CY, Liu CJ. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 2006;35:51-54
29. Su TH, Chang TY, Lee YJ, et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007;28:1237-1240
30. Nearman ZP, Wlodarski M, Jankowska AM, et al. Immunogenetic factors determining the evolution of Tcell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 2007;136:237-248 (Pubitemid 46020751)
31. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic Tlymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-2627 (Pubitemid 350250330)
32. Breunis WB, Tarazona-Santos E, Chen R, Kiley M, Rosenberg SA, Chanock SJ. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 2008;31: 586-590